MoffettNathanson Initiates Coverage On Datadog with Buy Rating, Announces Price Target of $143
MoffettNathanson analyst Jackson Ader initiates coverage on Datadog (NASDAQ:DDOG) with a Buy rating and announces Price Target of $143.
MoffettNathanson Initiates Coverage On CrowdStrike Holdings with Buy Rating, Announces Price Target of $280
MoffettNathanson analyst Jackson Ader initiates coverage on CrowdStrike Holdings (NASDAQ:CRWD) with a Buy rating and announces Price Target of $280.
MoffettNathanson Initiates Coverage On Okta with Sell Rating, Announces Price Target of $71
MoffettNathanson analyst Jackson Ader initiates coverage on Okta (NASDAQ:OKTA) with a Sell rating and announces Price Target of $71.
MoffettNathanson Initiates Coverage On Procore Technologies with Buy Rating, Announces Price Target of $73
MoffettNathanson analyst Sterling Auty initiates coverage on Procore Technologies (NYSE:PCOR) with a Buy rating and announces Price Target of $73.
MoffettNathanson Initiates Coverage On Zscaler with Hold Rating, Announces Price Target of $268
MoffettNathanson analyst Sterling Auty initiates coverage on Zscaler (NASDAQ:ZS) with a Hold rating and announces Price Target of $268.
MoffettNathanson Initiates Coverage On Zoom Video Comms with Sell Rating, Announces Price Target of $86
MoffettNathanson analyst Sterling Auty initiates coverage on Zoom Video Comms (NASDAQ:ZM) with a Sell rating and announces Price Target of $86.
Cowen & Co. Initiates Coverage On 23andMe Holding with Outperform Rating, Announces Price Target of $6
Cowen & Co. analyst Steven Mah initiates coverage on 23andMe Holding (NASDAQ:ME) with a Outperform rating and announces Price Target of $6.
Raymond James Initiates Coverage On MetLife with Market Perform Rating
Raymond James analyst Wilma Burdis initiates coverage on MetLife (NYSE:MET) with a Market Perform rating.
Goldman Sachs Initiates Coverage On Revance Therapeutics with Buy Rating, Announces Price Target of $33
Goldman Sachs analyst Chris Shibutani initiates coverage on Revance Therapeutics (NASDAQ:RVNC) with a Buy rating and announces Price Target of $33.
Citigroup Initiates Coverage On Gracell Biotechnologies with Buy Rating, Announces Price Target of $12
Citigroup analyst Yigal Nochomovitz initiates coverage on Gracell Biotechnologies (NASDAQ:GRCL) with a Buy rating and announces Price Target of $12.